Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer

Cancer Immunology, Immunotherapy

Volumn 52, Issue 9, 2003, Pages 535-545

  Ciavarra, Richard P ^a   Brown, Roy R ^a   Holterman, Daniel A ^a   Garrett, Marianne ^a   Glass II, William F ^a   Wright Jr , George L ^a,b   Schellhammer, Paul F ^a,b   Somers, Kenneth D ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Sentara Cancer Resource Centers   (United States)

Author keywords

4 1BB; CD40 ligand; flt3 ligand; TRAMP C1 tumor; Tumor microenvironment

Indexed keywords

CD3 ANTIGEN; CD3 EPSILON ANTIGEN; CD40 LIGAND; FLT3 LIGAND; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4 1BB; T LYMPHOCYTE RECEPTOR BETA CHAIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CELL INFILTRATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HELPER CELL; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SPLEEN CELL; TUMOR GROWTH; VACCINATION;

ANIMALS; CD40 LIGAND; CELL LINE, TUMOR; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS;

EID: 0042355174     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-003-0383-x     Document Type: Article

References (40)

1. Borges L, Miller RE, Jones J, Ariail K, Whitmore J, Fanslow W, Lynch DH (1999) Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo. J Immunol. 163: 1289
2. Brasel K, McKenna HJ, Morrissey PJ, Charrier K, Morris AE, Lee CC, Willliams DE, Lyman SD (1996) Hematologic effects of flt3 ligand in vivo in mice. Blood 88: 2004
3. Chaux P., Favre N., Martin M, Martin F (1997) Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int J Cancer 72: 619
4. +-dependent anti-independent T helper cell pathways in virus-specific and alloreactive cytotoxic T lymphocyte response. Cell Immunol 125: 363
5. - lymphocytes to hyperthermia following mitogen and antigen stimulation and its functional consequences on development of cytotoxic lymphocytes. Cell Immunol 107: 292
6. Ciavarra RP, Somers KD, Brown RR, Glass WF, de Angelis Consolvo PJ, Wright GL, Schellhammer PF (2000) Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer. Cancer Res 60: 2081
7. DeBenedette MA, Shahinian A, Mak TW, Watts TH (1997) Costimulation of CD28- T lymphocytes by 4-1BB ligand. J Immunol 158: 551
8. Diehl L, van Mierlo GJ, den Boer AT, van der Voort E, Fransen M, van Bostelen L, Krimpenfort P, Melief CJ, Mittler R, Toes RE, Offringa R (2002) In vivo triggering through 4-1BB enables Th-independent priming of CTL in the presence of an intact CD28 co-stimulatory pathway. J Immunol 168: 3755
9. Forni G., Lollini P. L., Musiani P., Colombo MP (2000) Immunoprevention of cancer: is the time ripe? Cancer Res 60: 2571
10. Foster BA, Gingrich JR, Kwon E., Madias C, Greenberg NM (1997) Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 57: 3325
11. Gaiger A, ReeseV, Disis ML, Cheever MA. (2000) Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 96: 1480
12. Gao L, Bellantuono I, Eisasser A, Marley SB, Gordon MY, Goldman JM, Stauss HJ (2000) Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95: 2198
13. Gastman BR., Johnson DE, Whiteside TL, Rabinowich H (1999) Caspase-mediated degradation of T-cell receptor zeta-chain. Cancer Res 59: 1422
14. Greenberg, NM, DeMayo F, Finegoldm MJ., Medina D., Tilley WD., Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM (1995) Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92: 3439
15. Grandis JR, Falkner DM, Melhem MF, Gooding WE, Drenning SD, Morel PA (2000) Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences. Clin Cancer Res 7: 2794
16. Grohmann U, Bianchi R, Belladonna ML, Vacca C, Silla S, Ayroldi E, Fioretti MC, Puccetti P (1999) IL-12 acts selectively on CD8α- dendritic cells to enhance presentation of a tumor peptide in vivo. J Immunol 163: 3100
17. Healy CG, Simons JW, Carducci MA, DeWeese T, Bartkowski M, Tong KP, Bolton WE (1998) Impaired expression and function of signal transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry 32: 109
18. Iiyoda T, Shimoyama S, Liu K, Omatsu Y, Akiyama Y, Maeda Y, Takahara K, Steinman RM, Inaba K (2002) The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med 195: 1289
19. Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjoberg J, Pisa P, Petersson M (1999) Tumor-induced immune dysfunction. Cancer Immunol Immunother 48: 353
20. Kono K, Ressing ME, Brandt RM, Melief CJ, Potkul RK, Amdersson B, Petersson M, Kast WM, Kiessling R (1996) Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res 2: 1825
21. Kopersztych S, Rexkallah MT, Miki SS, Naspitz CK, Mendes NF (1976) Cell mediated immunity in patients with carcinoma: correlation between clinical stage and immunocompetence. Cancer 38: 1149
22. Lai P, Rabinowich H,. Crowley-Nowick PA, Bell MC, Mantovani G, Whiteside TL (1996) Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res 2: 167
23. Le YS, Kim TE, Kim BK, Park YG, Kim GM, Jee SB, Ryu KS, Kim IK, Kim JW (2002) Alterations of HLA class I and class II antigen expressions in borderline, invasive and metastatic ovarian cancers. Exp Mol Med 34: 18
24. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JC (1997) Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med 6: 625
25. Mackey M, Barth RJ, Noelle RJ (1998) The role of CD40/CD154 interactions in the priming, differentiation and effector function of helper and cytotoxic T cells. J Leukocyte Biol 63: 418
26. Mackey MF, Gunn JR, Maliszewsky C, Kikutani H, Noelle RJ, Barth RJ Jr (1998) Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J Immunol 161: 2094
27. Matsuda M., Petersson M, Lenkei R, Taupin JL, Magnusson I, Mellstedt H, Anderson P, Kiessling R (1995) Alterations in the signal-transducing molecules of T cell and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer 61: 765.
28. Matzinger P (1991) The JAM test. A simple assay for DNA fragmentation and cell death. J Immunol Methods 145: 185
29. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, Mittler RS, Chen L (1997). Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 6: 682
30. Miga AJ, Masters SR, Durell BG, Conzalez M, Jenkins MK, Maliszewski C, Kikutani J, Wade WF, Noelle RJ (2001) Dendritic cell longevity and T cell persistence is controlled by CD154-CD40 interactions. Eur J Immunol 31: 959
31. Miller RE, Jones J, Le T, Whitmore J, Boiani N, Gliniak B, Lynch DH (2002). 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J Immunol. 169: 1792
32. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AA (1992) Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258: 1795
33. Murphy G, Tjoa B, Ragde J, Kenny G, Boynton A (1996) Phase I clinical trial: T cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 29: 371
34. Reichert TE, Day R, Wagner EM, Whiteside TL (1998) Absent or low expression of zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res 58: 5344
35. Reichert TE, Scheuer C, Day R, Wagner W, Whiteside TL (2001) The number of intratumoral dendritic cells and zeta chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 91: 2136
36. Ryu KS, Lee YS, Kim BK, Park YG, Kim YW, Hur SY, Kim TE, Kim IK, Kim JW (2001) Alterations of HLA class I and II antigen expression in pre-invasive, invasive and metastatic cervical cancers. Exp Mol Med 33: 136
37. Tan JT, Whitmire JK, Ahmed R, Pearson TC, Larsen CP (1999). 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses. J Immunol 163: 4859
38. Velders MP, Schrieber H, Kast WM (1998) Active immunization against cancer: impediments and advances. Semin Oncol 25: 697
39. Vicari AP, Chiodom D, Vaure C, Ait-Yahia S, Dercamp C, Matsos F, Reynard O, Taverne C, Merle P, Colombo MP, O'Garra A, Trinchiere G, Caux C (2002). Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anit-interleukin-10 receptor antibody. J.Exp Med 196: 541
40. Wilcox RA, Flies DB, Zhu G, Hohnson AJ, Tamada K, Chapoval AI, Strome SE, Pease LR, Chen L (2002) Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 109: 651